Allogenic Hematopoietic Cell Transplantation (Hct) Vs. Non-Hst Consolidation Therapies In Acute Myeloid Leukemia (Aml) Patients 60-75 Years Of Age In First Complete Remission (Cr1): An Alliance (A151509),Swog, Ecog-Acrin And Cibmtr Study

Introduction: The preferred post-remission therapy for older patients (pts) with AML remains uncertain. We compared outcomes for older AML pts in CR1 receiving HCT reported to the CIBMTR to older AML pts achieving CR1 on National Clinical Trials Network induction and non-HCT consolidation therapy (CT) trials.